July 12 (Reuters) - Sirona Biochem Corp SBM.V :
* SIRONA BIOCHEM ANNOUNCES CFDA APPROVAL OF SGLT2 INHIBITOR FOR PHASE I CLINICAL TRIAL
* SIRONA BIOCHEM CORP - IND SUBMISSION TO CHINA'S FOOD AND DRUG ADMINISTRATION (CFDA) FOR SGLT2 INHIBITOR WAS APPROVED FOR CLINICAL TRIAL
* SIRONA BIOCHEM CORP - CO'S PARTNER WANBANG WILL BE ENTERING PHASE I CLINICAL TRIAL FOR TREATMENT OF TYPE 2 DIABETES